We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > COV001

News List

Vaxzevria Induced Immunity for at Least One Year Following a Single Dose and Strong Immune Responses Following Either a Late Second Dose or a Third Dose drugs
July 08, 2021
A sub-analysis from the Oxford-led COV001 and COV002 trials with Vaxzevria induced strong immune responses following either a prolonged second dose interval of up to 45 weeks or following a third boosting dose.
A Single Dose of Vaxzevria Induced Immunity for One Year, Second and Third Dose Increase Response americanpharmaceuticalreview
June 30, 2021
Oxford-led COV001 and COV002 trials showed that Vaxzevria induced a strong immune response following a long second dose interval (up to 45 weeks) and after a third booster dose.
COVID-19 vaccine AZD1222 showed robust immune responses in all participants in Phase I/II trial worldpharmanews
July 21, 2020
Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-CoV-2 virus in all evaluated participants.